Literature DB >> 33104021

Long noncoding RNA MAGI2-AS3 inhibits bladder cancer progression through MAGI2/PTEN/epithelial-mesenchymal transition (EMT) axis.

Daqing Shen1,2, Jing Xu2, Xiande Cao2, Xianxiang Cao2, Hailin Tan1, Huanghao Deng3.   

Abstract

BACKGROUND: Long noncoding RNA (lncRNA) are critical regulators of tumor progression.
OBJECTIVE: To determine how the lncRNA membrane associated guanylate kinase, WW and PDZ domain-containing 2 (MAG12) antisense RNA 3 (MAGI2-AS3) and the phosphatase and tensin homolog (PTEN) gene function in regulating bladder cancer (Bca) progression.
METHODS: Total RNA from 80 Bca tissues and 30 paired para-cancerous tissues from patients was sequentially extracted, quantified, purified, and reverse transcribed using RT-PCR. A library was constructed and sequenced. Four Bca cell lines and a normal urothelial cell line were transfected with lentiviral plasmids, and cell migration and invasion were assayed in vitro. An orthotopic mouse model of Bca was created for in vivo studies.
RESULTS: MAGI2-AS3 expression was significantly downregulated in Bca, compared with normal tissues, and negatively associated with tumor stage and a poor prognosis. MAGI2-AS3 and its sense RNA MAGI2 showed significant and positive correlation. The expression of MAGI2 and its downstream gene, PTEN, increased in Bca cells overexpressing MAGI2-AS3, and interference by MAGI2 expression reversed the migration and invasion inhibited by MAGI2-AS3 overexpression.
CONCLUSION: MAGI2-AS3 overexpression inhibited Bca cell progression by regulating the MAGI2/PTEN/epithelial-mesenchymal transition, offering novel insights into the mechanism of Bca progression.

Entities:  

Keywords:  Bladder cancer; MAGI2-AS3; lncRNA; progression

Year:  2021        PMID: 33104021     DOI: 10.3233/CBM-201421

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  4 in total

1.  LncRNA MAGI2-AS3 acts as a tumor suppressor that attenuates non-small cell lung cancer progression by targeting the miR-629-5p/TXNIP axis.

Authors:  Jun Gong; Lei Ma; Chunlei Peng; Jianhua Liu
Journal:  Ann Transl Med       Date:  2021-12

2.  A Radioresponse-Related lncRNA Biomarker Signature for Risk Classification and Prognosis Prediction in Non-Small-Cell Lung Cancer.

Authors:  Jiahang Song; Shuming Zhang; Yuanyuan Sun; Junjie Gu; Ziqi Ye; Xinchen Sun; Qiyun Tang
Journal:  J Oncol       Date:  2021-09-21       Impact factor: 4.375

Review 3.  Emerging role of lncRNAs in drug resistance mechanisms in head and neck squamous cell carcinoma.

Authors:  José A Peña-Flores; Mercedes Bermúdez; Rosalío Ramos-Payán; Carlos E Villegas-Mercado; Uriel Soto-Barreras; Daniela Muela-Campos; Alexis Álvarez-Ramírez; Brenda Pérez-Aguirre; Ana D Larrinua-Pacheco; César López-Camarillo; Jorge A López-Gutiérrez; Julio Garnica-Palazuelos; Marvin E Estrada-Macías; Juan L Cota-Quintero; Andrés A Barraza-Gómez
Journal:  Front Oncol       Date:  2022-08-01       Impact factor: 5.738

4.  Circular RNA circSETD3 hampers cell growth, migration, and stem cell properties in bladder cancer through sponging miR-641 to upregulate PTEN.

Authors:  Ying Tian; Ping Gao; Di Dai; Lan Chen; Xin Chu; Xuefeng Mei
Journal:  Cell Cycle       Date:  2021-07-21       Impact factor: 5.173

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.